Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients

Cytokine

Volumn 62, Issue 2, 2013, Pages 232-243

  Pavón, Esther J ^a,g   Zumaquero, Esther ^a,h   Rosal Vela, Antonio ^a   Khoo, Keng Meng ^b,i   Cerezo Wallis, Daniela ^a   García Rodríguez, Sonia ^a   Carrascal, Montserrat ^c   Abian, Joaquin ^c   Graeff, Richard ^d   Callejas Rubio, José Luis ^e   Ortego Centeno, Norberto ^e   Malavasi, Fabio ^f   Zubiaur, Mercedes ^a   Sancho, Jaime ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c CSIC   (Spain)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f UNIVERSITY OF TURIN   (Italy)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h University of Alabama at Birmingham   (United States)

ⁱ Singapore Science Park II   (Singapore)

Author keywords

Anti CD38 autoantibodies; CD38; Cytokine profiles; IL 10; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CD38 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ANTINUCLEAR ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ALPHA;

ANTIBODY BLOOD LEVEL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; UPREGULATION; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

MAMMALIA;

ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD38; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 84876797511     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.023     Document Type: Article

References (48)

1. Malavasi F., Deaglio S., Funaro A., Ferrero E., Horenstein A.L., Ortolan E., et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008, 88:841-886.
2. Khoo K.M., Chang C.F. Characterization and localization of CD38 in the vertebrate eye. Brain Res. 1999, 821:17-25.
3. Khoo K.M., Chang C.F. Localization of plasma membrane CD38 is domain specific in rat hepatocyte. Arch Biochem Biophys. 2000, 373:35-43.
4. Graeff R., Munshi C., Aarhus R., Johns M., Lee H.C. A single residue at the active site of CD38 determines its NAD cyclizing and hydrolyzing activities. J Biol Chem 2001, 276:12169-12173.
5. Lee H.C. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol 2001, 41:317-345.
6. Guse A.H. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). Febs J. 2005, 272:4590-4597.
7. Dammermann W., Zhang B., Nebel M., Cordiglieri C., Odoardi F., Kirchberger T., et al. NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. PNAS 2009, 106:10678-10683.
8. Giorgi J.V., Lyles R.H., Matud J.L., Yamashita T.E., Mellors J.W., Hultin L.E., et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002, 29:346-355.
9. Keyhani A., Huh Y.O., Jendiroba D., Pagliaro L., Cortez J., Pierce S., et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 2000, 24:153-159.
10. Deaglio S., Vaisitti T., Aydin S., Ferrero E., Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006, 108:1135-1144.
11. Deaglio S., Aydin S., Vaisitti T., Bergui L., Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med 2008, 14:210-218.
12. Grammer A.C., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
13. Lee J., Kuchen S., Fischer R., Chang S., Lipsky P.E. Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol 2009, 182:4116-4126.
14. Spronk P.E., Horst G., Van Der Gun B.T., Limburg P.C., Kallenberg C.G. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol 1996, 104:446-453.
15. +-consuming ectoenzymes in the endocrine system. J Mol Endocrinol 2010, 45:183-191.
16. Alcocer-Varela J., Alarcon-Riquelme M., Laffon A., Sanchez-Madrid F., Alarcon-Segovia D. Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus. Correlation with proliferative responses and production of IL-2. J Autoimmun 1991, 4:935-945.
17. al-Janadi M., Raziuddin S. B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus. J Rheumatol 1993, 20:1885-1891.
18. Pavon E.J., Munoz P., Navarro M.D., Raya-Alvarez E., Callejas-Rubio J.L., Navarro-Pelayo F., et al. Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells. Mol Immunol 2006, 43:1029-1039.
19. Ikehata F., Satoh J., Nata K., Tohgo A., Nakazawa T., Kato I., et al. Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin-dependent diabetes patients. J Clin Invest 1998, 102:395-401.
20. Mallone R., Ortolan E., Baj G., Funaro A., Giunti S., Lillaz E., et al. Autoantibody response to CD38 in Caucasian patients with type 1 and type 2 diabetes: immunological and genetic characterization. Diabetes 2001, 50:752-762.
21. Antonelli A., Fallahi P., Nesti C., Pupilli C., Marchetti P., Takasawa S., et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001, 126:426-431.
22. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992, 35:630-640.
23. Khoo K.M., Chang C.F., Schubert J., Wondrak E., Chng H.H. Expression and purification of the recombinant His-tagged GST-CD38 fusion protein using the baculovirus/insect cell expression system. Protein Expr Purif 2005, 40:396-403.
24. Fryxell K.B., O'Donoghue K., Graeff R.M., Lee H.C., Branton W.D. Functional expression of soluble forms of human CD38 in Escherichia coli and Pichia pastoris. Protein Expr Purif 1995, 6:329-336.
25. Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J. Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment. J Proteome Res 2008, 7:5167-5176.
26. Munoz P., Mittelbrunn M., de la Fuente H., Perez-Martinez M., Garcia-Perez A., Ariza-Veguillas A., et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 2008, 111:3653-3664.
27. Morra M., Zubiaur M., Terhorst C., Sancho J., Malavasi F. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J 1998, 12:581-592.
28. Ausiello C.M., Urbani F., la Sala A., Funaro A., Malavasi F. CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur J Immunol 1995, 25:1477-1480.
29. Illei G.G., Tackey E., Lapteva L., Lipsky P.E. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004, 50:2048-2065.
30. Letourneau S., Krieg C., Pantaleo G., Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009, 123:758-762.
31. + T cells induce polyclonal Ig production by committed human B cells. Enhancement by IL-5, specific inhibition of IgA synthesis by IL-4. J Immunol 1992, 148:1674-1684.
32. Zubiaur M., Izquierdo M., Terhorst C., Malavasi F., Sancho J. CD38 ligation results in activation of the Raf-1/mitogen-activated protein kinase and the CD3-zeta/zeta-associated protein-70 signaling pathways in Jurkat T lymphocytes. J Immunol 1997, 159:193-205.
33. Lydyard P.M., Lamour A., MacKenzie L.E., Jamin C., Mageed R.A., Youinou P. CD5+ B cells and the immune system. Immunol Lett 1993, 38:159-166.
34. Rekvig O.P., Putterman C., Casu C., Gao H.X., Ghirardello A., Mortensen E.S., et al. Autoantibodies in lupus: culprits or passive bystanders. Autoimmun Rev 2011.
35. Meroni P.L., Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010, 10:1-2.
36. Morimoto A.M., Flesher D.T., Yang J., Wolslegel K., Wang X., Brady A., et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:2407-2415.
37. von Wussow P., Jakschies D., Hartung K., Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988, 8:225-230.
38. Ching K.H., Burbelo P.D., Tipton C., Wei C., Petri M., Sanz I., et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 2012, 7:e32001.
39. Gronwall C., Akhter E., Oh C., Burlingame R.W., Petri M., Silverman G.J. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol 2012, 142:390-398.
40. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140.
41. Tirumurugaan K.G., Kang B.N., Panettieri R.A., Foster D.N., Walseth T.F., Kannan M.S. Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-alpha and dexamethasone. Respir Res 2008, 9:26.
42. Musso T., Deaglio S., Franco L., Calosso L., Badolato R., Garbarino G., et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001, 69:605-612.
43. Deshpande D.A., Dogan S., Walseth T.F., Miller S.M., Amrani Y., Panettieri R.A., et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004, 31:36-42.
44. Bauvois B., Durant L., Laboureau J., Barthelemy E., Rouillard D., Boulla G., et al. Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J Interferon Cytokine Res 1999, 19:1059-1066.
45. Trepiakas R., Pedersen A.E., Met O., Svane I.M. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 2009, 27:2213-2219.
46. Boasso A., Hardy A.W., Anderson S.A., Dolan M.J., Shearer G.M. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 2008, 3:e2961.
47. Tliba O., Cidlowski J.A., Amrani Y. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Mol Pharmacol 2006, 69:588-596.
48. Tenbrock K., Juang Y.T., Kyttaris V.C., Tsokos G.C. Altered signal transduction in SLE T cells. Rheumatology (Oxford, England) 2007, 46:1525-1530.